Please login to the form below

Not currently logged in
Email:
Password:

Pradaxa

This page shows the latest Pradaxa news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Ingelheim’s thrombin inhibitor Pradaxa (dabigatran).

Latest news

More from news
Approximately 22 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    At least the $225m will go some way towards paying for the $650m settlement of the US Pradaxa litigation Boehringer announced in May.

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    So far in 2013 the company has seen continued growth of its next-generation anticoagulant Pradaxa against fierce competition from rival drugs from Bristol-Myers Squibb/Pfizer and Bayer; pledged to ... American College of Cardiology (ACC) to educate

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Dabigatran etexilate. Notwithstanding the initial setback for DTIs, Boehringer Ingelheim (BI) first launched its twice-daily DTI prodrug, dabigatran etexilate (Pradaxa/Pradax), in 2008.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Frontera proud finalists for the 2020 PM Awards Frontera proud finalists for the 2020 PM Awards

    Meanwhile, the agency’s extensive work across multiple Boehringer Ingelheim products including Pradaxa, Spiolto and OFEV were also recognised in Film &Animation (HCPs), Mixed Media Campaign and Sales Aid categories.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics